DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Albinterferon
Albinterferon
Current Therapies for Chronic Hepatitis C
Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation
7 Engineering of Therapeutic Proteins
Part One General Information
Interferon in Inflammatory Diseases
Translational Genomics, Transcriptomics and Metabolomics Analyses of the Metabolic Effects of Chronic Hepatitis C Infection and Their Clinical Implications
(INN) for Biological and Biotechnological Substances
A Potent in Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon
Randomized Trial of Albinterferon Alfa2b Every 4Weeks for Chronic
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Statistical Analysis Plan P15-698
Dysregulation of Innate Immunity in Hepatitis C Virus Genotype 1 IL28B-Unfavorable Genotype Patients: Impaired Viral Kinetics and Therapeutic Response
Molecular Engineering of Therapeutic Cytokines
Withdrawal of the Marketing Authorisation Application for Joulferon (Albinterferon Alfa-2B)
Human Genome Sciences 2008 Annual Report
Interferon in Inflammatory Diseases
Assessing the History and Value of Human Genome Sciences Received: May 23, 2013
Immune-Modulators to Combat Hepatitis B Virus Infection: From
Top View
Overview of Interferon: Characteristics, Signaling and Anti
The Way Forward in HCV Treatment — Finding the Right Path
Current and Future Treatment Options for HCV
The Future Use of Interferon in the Treatment of Hepatitis C: New Formulations, New Combinations
Us 2018 / 0271910 A1
WO 2015/153102 Al 8 October 2015 (08.10.2015) P O P C T
(INN) for Biological and Biotechnological Substances
Interferons As Therapeutic Agents in Infectious Diseases Mckenzie C
Large-Scale Production of Functional Human Serum Albumin from Transgenic Rice Seeds
Albinterferon Alfa-2B (Joulferon) for Hepatitis C with Compensated Liver Disease
Efficacy and Safety of a Novel Pegylated Interferon Alpha-2A in Egyptian Patients with Genotype 4 Chronic Hepatitis C
The Yin and Yang of Type I Ifns in Cancer Promotion and Immune Activation
Serum Albumin As a Local Therapeutic Agent in Cell Therapy and Tissue